|Articles|August 1, 2019
- Pharmaceutical Executive-08-01-2019
- Volume 39
- Issue 8
Pharmaceutical Executive, August 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive August 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 7 years ago
A Look Back & Forward on Innovationalmost 7 years ago
Routes to Exclusivity in Cell-Based Therapy Developmentalmost 7 years ago
Gene Therapy: Managing the Clinical Trial Minefieldsalmost 7 years ago
The Call to Cure: Geoff MacKay, AVROBIOalmost 7 years ago
Four Takeaways from the Zolgensma Pricing Stormalmost 7 years ago
FDA Faces ‘Explosion’ in Growth of Gene Therapiesalmost 7 years ago
Mapping Out the Future of Cell and Gene Therapyalmost 7 years ago
High-Stakes Manufacturing: Mitigating the Risksalmost 7 years ago
Gene Therapy: How ‘Advanced’ is Europe?almost 7 years ago
Luxturna: A Vision for Curative Therapy AccessAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Lipfendra to reduce LDL-C in Adults with Hypercholesterolemia
2
Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement
3
Pharmaceutical Executive Daily: FDA Approves Lipfendra
4
From Dr. Google to Dr. Claude: Why the Most Important Patient Support Innovation Is Still Human Connection
5